NANJING, China, March 1 Simcere Pharmaceutical Group(NYSE: SCR), a leading pharmaceutical company specializing in the development,manufacturing, and marketing of branded generic and proprietarypharmaceuticals in China, today announced that it will report its unauditedfinancial results for the fourth quarter and fiscal year ended December 31,2009, on Tuesday, March 16, 2010, before the market opens in the United States.Simcere's Chief Executive Officer, Jinsheng Ren, and Chief Financial Officer,Frank Zhigang Zhao, will host an earnings conference call on the same day, at8 a.m. ET (Tuesday, March 16, at 8 p.m. Beijing/Hong Kong time).
Please ask to be connected to Q4 2009 Simcere Pharmaceutical GroupEarnings Conference Call and provide the following passcode: 65611658.
Simcere will also broadcast a live audio webcast of the conference call.The broadcast will be available by visiting the "Investor Relations" sectionof the company's web site at http://www.simcere.com .
The passcode for replay participants is: 88577131. The telephone replayalso will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leadingpharmaceutical company specializing in the development, manufacturing, andmarketing of branded generic and proprietary pharmaceuticals in China. Inrecent years, Simcere has been focusing its strategy on the development ofinnovative pharmaceuticals and first-to-market generics, and has introduced aninnovative anti-cancer medication Endu, a first-to-market medication Sinofuan,and first-to-market generics such as Bicun and Anxin. Simcere manufactures andsells antibiotics, anti-cancer medication, stroke management medication andbiopharmaceutical drugs such as vaccines. Simcere concentrates its researchand development efforts on the treatment of diseases with high incidenceand/or mortality rates and for which there is a clear demand for moreeffective pharmacotherapy such as cancer, strokes, orthopaedics and infectiousdiseases. For more information about Simcere Pharmaceutical Group, pleasevisit http://www.simcere.com .To access the conference call, please dial: United States toll-free: +1.800.901.5213 International: +1.617.786.2962 North China toll-free: 10.800.152.1490 South China toll-free: 10.800.130.0399 China toll free / Netcom: 10 800 852 1490 Hong Kong: +852.3002.1672
SOURCE Simcere Pharmaceutical Group